Terms: = Lung cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Treatment
2426 results:
1. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
3. Recording and classifying met receptor mutations in cancers.
Guérin C; Tulasne D
Elife; 2024 Apr; 13():. PubMed ID: 38652103
[TBL] [Abstract] [Full Text] [Related]
4. Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study.
Resova K; Knybel L; Parackova T; Rybar M; Cwiertka K; Cvek J
Radiat Oncol; 2024 Apr; 19(1):50. PubMed ID: 38637844
[TBL] [Abstract] [Full Text] [Related]
5. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell lung cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
[TBL] [Abstract] [Full Text] [Related]
6. [Clinical characteristics and prognosis analysis of pulmonary sarcomatoid carcinoma].
Feng XY; Chen MJ; Xu Y; Zhong W; Liu XY; Gao XX; Zhao J; Wang MZ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):319-324. PubMed ID: 38599806
[No Abstract] [Full Text] [Related]
7. Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S; Shinada K; Otsutsumi Y; Komine F; Yuan Y; Nakamura J; Katakura S; Kondo T; Kato T; Yokose T; Saito H
Cancer Med; 2024 Apr; 13(7):e7162. PubMed ID: 38572952
[TBL] [Abstract] [Full Text] [Related]
8. Patterns and treatment outcomes of primary bone tumors in children treated at tertiary referral hospital, Ethiopia.
Lingerih T; Yeshiwas S; Mohamedsaid A; Arega G
BMC Cancer; 2024 Mar; 24(1):394. PubMed ID: 38549062
[TBL] [Abstract] [Full Text] [Related]
9. Mobocertinib: Mechanism of action, clinical, and translational science.
Hanley MJ; Camidge DR; Fram RJ; Gupta N
Clin Transl Sci; 2024 Mar; 17(3):e13766. PubMed ID: 38511563
[TBL] [Abstract] [Full Text] [Related]
10. From osimertinib to preemptive combinations.
Blagosklonny MV
Oncotarget; 2024 Mar; 15():232-237. PubMed ID: 38497774
[TBL] [Abstract] [Full Text] [Related]
11. Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care treatments in Patients with Advanced Non-small Cell lung cancer (NSCLC) Harbouring metex14 Skipping in the UK.
Batteson R; Hook E; Wheat H; Hatswell AJ; Vioix H; McLean T; Alexopoulos ST; Baijal S; Paik PK
Target Oncol; 2024 Mar; 19(2):191-201. PubMed ID: 38492157
[TBL] [Abstract] [Full Text] [Related]
12. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and met exon 14 skipping in NSCLC.
Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
[TBL] [Abstract] [Full Text] [Related]
13. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell lung cancer Cells by Inhibiting MCL-1 Expression via met/STAT3/Akt Pathway.
Wang L; Xu L; Han S; Zhu X
Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
[TBL] [Abstract] [Full Text] [Related]
14. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
[TBL] [Abstract] [Full Text] [Related]
15. UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.
Haakensen VD; Öjlert ÅK; Thunold S; Farooqi S; Nowak AK; Chin WL; Grundberg O; Szejniuk WM; Cedres S; Sørensen JB; Dalen TS; Lund-Iversen M; Bjaanæs M; Helland Å
Eur J Cancer; 2024 May; 202():113973. PubMed ID: 38447379
[TBL] [Abstract] [Full Text] [Related]
16. Distinct fibroblast subpopulations associated with bone, brain or intrapulmonary metastasis in advanced non-small-cell lung cancer.
Xu K; Wang H; Zou YX; Zhang HH; Wang YN; Ren XR; Wang HQ; Xu YH; Li JJ; Tang H; He C; Wei S; Tian T; Li LL; Zhou H; Xu LJ; Fang JW; Guo C; Yang JX; Zhou YY; Zhang ZH; Pan YY
Clin Transl Med; 2024 Mar; 14(3):e1605. PubMed ID: 38445456
[TBL] [Abstract] [Full Text] [Related]
17. Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell lung cancer.
Zhao X; Zhang X; Chen H; Bao H; Wu X; Wang H; Bao H; Pang J; Wang S; Wang J
Clin Chem; 2024 Apr; 70(4):629-641. PubMed ID: 38416709
[TBL] [Abstract] [Full Text] [Related]
18. Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.
Han R; Lin C; Lu C; Wang Y; Kang J; Hu C; Dou Y; Wu D; He T; Tang H; Zheng J; Li L; He Y
Cancer Lett; 2024 Apr; 588():216762. PubMed ID: 38408602
[TBL] [Abstract] [Full Text] [Related]
19. Long-term experience with tepotinib in Japanese patients with met exon 14 skipping NSCLC from the Phase II VISION study.
Morise M; Kato T; Matsumoto S; Inoue T; Sakamoto T; Tokito T; Atagi S; Kozuki T; Takeoka H; Chikamori K; Shinagawa N; Tanaka H; Horii E; Adrian S; Bruns R; Johne A; Paik PK; Sakai H
Cancer Sci; 2024 Apr; 115(4):1296-1305. PubMed ID: 38402853
[TBL] [Abstract] [Full Text] [Related]
20. Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study.
Jiang K; Wu L; Zheng X; Xu Y; Miao Q; Zheng X; Zhang L; Huang C; Lin G
BMC Pulm Med; 2024 Feb; 24(1):96. PubMed ID: 38402169
[TBL] [Abstract] [Full Text] [Related]
[Next]
